Ketamine and Midazolam Infusions for CRPS: Feasibility Study
Status:
Withdrawn
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This study will assess the feasibility of administering ketamine plus midazolam or midazolam
alone, when infused over 5 days in an outpatient setting, to adults with complex regional
pain syndrome (CRPS).